Department of Chemistry, Jess and Mildred Fisher College of Science and Mathematics, Towson University, Towson, Maryland 21252, United States.
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland 21201, United States.
J Chem Theory Comput. 2024 Jul 9;20(13):5528-5538. doi: 10.1021/acs.jctc.4c00290. Epub 2024 Jun 15.
Acrylamides are the most commonly used warheads of targeted covalent inhibitors (TCIs) directed at cysteines; however, the reaction mechanisms of acrylamides in proteins remain controversial, particularly for those involving protonated or unreactive cysteines. Using the combined semiempirical quantum mechanics (QM)/molecular mechanics (MM) free energy simulations, we investigated the reaction between afatinib, the first TCI drug for cancer treatment, and Cys797 in the EGFR kinase. Afatinib contains a β-dimethylaminomethyl (β-DMAM) substitution which has been shown to enhance the intrinsic reactivity and potency against EGFR for related inhibitors. Two hypothesized reaction mechanisms were tested. Our data suggest that Cys797 becomes deprotonated in the presence of afatinib, and the reaction proceeds via a classical Michael addition mechanism, with Asp800 stabilizing the ion-pair reactant state β-DMAM/C797 and the transition state of the nucleophilic attack. Our work elucidates an important structure-activity relationship of acrylamides in proteins.
丙烯酰胺是目前应用最广泛的靶向半胱氨酸的共价抑制剂(TCIs)的弹头;然而,丙烯酰胺在蛋白质中的反应机制仍存在争议,特别是对于涉及质子化或非反应性半胱氨酸的反应机制。我们使用组合半经验量子力学(QM)/分子力学(MM)自由能模拟方法,研究了 afatinib(首个用于癌症治疗的 TCI 药物)与 EGFR 激酶中 Cys797 的反应。Afatinib 含有β-二甲基氨甲基(β-DMAM)取代基,已被证明可增强相关抑制剂对 EGFR 的固有反应性和效力。我们测试了两种假设的反应机制。我们的数据表明,在 afatinib 的存在下,Cys797 去质子化,反应通过经典的迈克尔加成机制进行,Asp800 稳定离子对反应物态β-DMAM/C797 和亲核进攻的过渡态。我们的工作阐明了蛋白质中丙烯酰胺的重要结构-活性关系。